Logo image of ARTV

ARTIVA BIOTHERAPEUTICS INC (ARTV) Stock Price, Quote, News and Overview

NASDAQ:ARTV - Nasdaq - US04317A1079 - Common Stock - Currency: USD

5.36  +0.26 (+5.1%)

After market: 5.45 +0.09 (+1.68%)

ARTV Quote, Performance and Key Statistics

ARTIVA BIOTHERAPEUTICS INC

NASDAQ:ARTV (3/7/2025, 8:05:38 PM)

After market: 5.45 +0.09 (+1.68%)

5.36

+0.26 (+5.1%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week HighN/A
52 Week LowN/A
Market Cap130.19M
Shares24.29M
Float17.68M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO07-19 2024-07-19


ARTV short term performance overview.The bars show the price performance of ARTV in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20 40 -40

ARTV long term performance overview.The bars show the price performance of ARTV in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of ARTV is 5.36 USD. In the past month the price increased by 16.52%.

ARTIVA BIOTHERAPEUTICS INC / ARTV Daily stock chart

ARTV Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 21.17 378.30B
AMGN AMGEN INC 16.39 174.51B
GILD GILEAD SCIENCES INC 25.47 146.22B
VRTX VERTEX PHARMACEUTICALS INC 1683.76 125.39B
REGN REGENERON PHARMACEUTICALS 15.5 77.34B
ARGX ARGENX SE - ADR 231.21 36.10B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 31.66B
ONC BEIGENE LTD-ADR N/A 26.47B
BNTX BIONTECH SE-ADR N/A 26.08B
BIIB BIOGEN INC 9.13 22.01B
NTRA NATERA INC N/A 19.02B
GMAB GENMAB A/S -SP ADR 24.89 15.34B

About ARTV

Company Profile

ARTV logo image Artiva Biotherapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Diego, California and currently employs 82 full-time employees. The company went IPO on 2024-07-19. Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. The firm's product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as LN, RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, SLE and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in class III or IV lupus nephritis (LN) and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.

Company Info

ARTIVA BIOTHERAPEUTICS INC

5505 Morehouse Drive

San Diego CALIFORNIA US

Employees: 82

Company Website: https://www.artivabio.com/

Phone: 18582674467

ARTIVA BIOTHERAPEUTICS INC / ARTV FAQ

What is the stock price of ARTIVA BIOTHERAPEUTICS INC today?

The current stock price of ARTV is 5.36 USD. The price increased by 5.1% in the last trading session.


What is the ticker symbol for ARTIVA BIOTHERAPEUTICS INC stock?

The exchange symbol of ARTIVA BIOTHERAPEUTICS INC is ARTV and it is listed on the Nasdaq exchange.


On which exchange is ARTV stock listed?

ARTV stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ARTIVA BIOTHERAPEUTICS INC stock?

12 analysts have analysed ARTV and the average price target is 21.42 USD. This implies a price increase of 299.63% is expected in the next year compared to the current price of 5.36. Check the ARTIVA BIOTHERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ARTIVA BIOTHERAPEUTICS INC worth?

ARTIVA BIOTHERAPEUTICS INC (ARTV) has a market capitalization of 130.19M USD. This makes ARTV a Micro Cap stock.


How many employees does ARTIVA BIOTHERAPEUTICS INC have?

ARTIVA BIOTHERAPEUTICS INC (ARTV) currently has 82 employees.


What are the support and resistance levels for ARTIVA BIOTHERAPEUTICS INC (ARTV) stock?

ARTIVA BIOTHERAPEUTICS INC (ARTV) has a resistance level at 6.51. Check the full technical report for a detailed analysis of ARTV support and resistance levels.


Is ARTIVA BIOTHERAPEUTICS INC (ARTV) expected to grow?

The Revenue of ARTIVA BIOTHERAPEUTICS INC (ARTV) is expected to decline by -99.19% in the next year. Check the estimates tab for more information on the ARTV EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ARTIVA BIOTHERAPEUTICS INC (ARTV) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ARTIVA BIOTHERAPEUTICS INC (ARTV) stock pay dividends?

ARTV does not pay a dividend.


What is the Price/Earnings (PE) ratio of ARTIVA BIOTHERAPEUTICS INC (ARTV)?

ARTIVA BIOTHERAPEUTICS INC (ARTV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.52).


What is the Short Interest ratio of ARTIVA BIOTHERAPEUTICS INC (ARTV) stock?

The outstanding short interest for ARTIVA BIOTHERAPEUTICS INC (ARTV) is 6.58% of its float. Check the ownership tab for more information on the ARTV short interest.


ARTV Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to ARTV.


Chartmill TA Rating
Chartmill Setup Rating

ARTV Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to ARTV. While ARTV seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ARTV Financial Highlights

Over the last trailing twelve months ARTV reported a non-GAAP Earnings per Share(EPS) of -3.52. The EPS increased by 51.15% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -34.57%
ROE -38.81%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%N/A
Sales Q2Q%N/A
EPS 1Y (TTM)51.15%
Revenue 1Y (TTM)579.21%

ARTV Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 85% to ARTV. The Buy consensus is the average rating of analysts ratings from 12 analysts.

For the next year, analysts expect an EPS growth of -339.32% and a revenue growth -99.19% for ARTV


Ownership
Inst Owners84.84%
Ins Owners0.73%
Short Float %6.58%
Short Ratio15.39
Analysts
Analysts85
Price Target21.42 (299.63%)
EPS Next Y-339.32%
Revenue Next Year-99.19%